Navigation Links
European Multidisciplinary Conference in Thoracic Oncology -- press program
Date:2/23/2011

The following studies will be presented in the Press Program of the second European Multidisciplinary Conference in Thoracic Oncology, a multipartner initiative for physicians of all medical disciplines dealing with lung cancer and other thoracic malignancies.

The full text of the embargoed press releases/abstracts can be requested to the EMCTO Press Office at media@esmo.org. When the embargo lifts, the texts will be available in the ESMO Online Newsroom.

  1. Quick, easy test identifies aggressive type of lung cancer in never-smokers (embargo: 25 February 2011, 8:00 CET)
    Inexpensive and rapid test can effectively identify sub-group of never-smoking lung cancer patients whose tumors express molecule associated with increased risk of disease progression or recurrence.
    Author: Ping Yang, US

  2. Oncogene AEG-1 strongly predicts response to erlotinib treatment in EGFR-mutant lung cancer (embargo: 25 February 2011, 8:00 CET)
    Researchers identified a gene whose expression level strongly predicts how well and how long certain lung cancer patients will respond to treatment with erlotinib.
    Author: Rafael Rosell, Spain

  3. Bone drug zoledronic acid may help prevent spread of early lung cancer (embargo: 25 February 2011, 8:00 CET)
    Drug currently used to help treat bone metastases in patients with lung cancer could also be useful at an earlier state of treatment to prevent cancer from spreading.
    Author: Michela Quirino, italy

  4. Radio-guided surgery, a safe and simple way to remove potentially cancerous nodules in the lung (embargo: 26 February 2011, 8:00 CET)
    Using tiny spheres of radioactive liquid to guide surgeons as they remove potentially cancerous material in the lungs is safe and more effective than other techniques.
    Author: Luca Bertolaccini, Italy

  5. Phase III trial: erlotinib as effective as chemo, with fewer side-effects, in patients whose disease progressed after first-line treatment (embargo: 26 February 2011, 8:00 CET)
    Targeted cancer drug erlotinib has comparable efficacy to chemotherapy and is better tolerated in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy.
    Author: Tudor Ciuleanu, Romania


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. IOF calls on European citizens to stand tall and speak out for their bones
2. IronKey Opens New European Office
3. European researchers harness unique properties of boron to develop new drugs and diagnostics
4. Vidaza receives positve opinion from European CHMP
5. The MDS foundation supports vidazas recommendation for European approval
6. European biodiversity and ecosystem scientists merge and gear up for long-term research
7. Overfishing threatens European bluefin tuna
8. European ancestry increases breast cancer risk among Latinas
9. IRB Barcelona to coordinate two European projects on biomedicine
10. Key to future medical breakthroughs is systems biology, say leading European scientists
11. Global warming linked to European viral epidemic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... June 27, 2016  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... the United States denied its petition ... claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") ... established by the Supreme Court,s Mayo Collaborative Services v. ...
(Date:6/27/2016)... Chapel Hill, N.C. (PRWEB) , ... June 27, ... ... of U.S. commercial operations for Amgen, will join the faculty of the ... will serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... Wausau, WI (PRWEB) , ... June 23, 2016 ... ... probiotic supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, ... supplements for over 35 years, is proud to add Target to its list ...
Breaking Biology Technology: